J. Sohn

发表

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.

W. Symmans, H. Rugo, S. Loibl, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

P. Fasching, H. Rugo, K. Tamura, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.

B. Cho, H. Choi, J. Ahn, 2006, Oncology reports.

236O_PRMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

M. Goetz, M. Campone, J. Huober, 2017 .

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

A. Bardia, A. Montero, J. Martinalbo, 2022, Annals of Oncology.

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

J. Huober, O. Trédan, S. Paluch-Shimon, 2022, Annals of Oncology.

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

E. Tokunaga, F. Cottone, W. Jacot, 2022, Annals of Oncology.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen

J. Roh, B. Cho, S. E. Park, 2005, Yonsei medical journal.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer

E. Tokunaga, M. Basik, N. Niikura, 2023, ESMO open.

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Tong Xu, L. Molinero, K. Punie, 2023, ESMO Open.